Intellia seeks FDA approval for in vivo CRISPR therapy [Yahoo! Finance]
DHI Group, Inc. (DHX)
Last dhi group, inc. earnings: 2/5 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
dhigroupinc.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
treatment for hereditary angioedema that would become the first in vivo CRISPR-based gene editing therapy if cleared by regulators. Positive Phase 3 HAELO trial results paved the way for the filing, with lonvo-z cutting the rate of hereditary angioedema attacks by 87% against placebo across a six-month evaluation window, Intellia said. The trial met its primary and all key secondary endpoints. At the six-month mark, 62% of lonvo-z recipients achieved attack-free status without other therapies, compared with only 11% of placebo patients, according to Biospace Regarding safety, Intellia characterized the lonvo-z tolerability data as "favorable," with infusion-related reactions, headaches, and fatigue among the most common adverse events. No serious side effects emerged, and the company disclosed no instances of liver toxicity. Liver safety had been a focus for analysts following a patient death in a separate trial of a different Intellia treatment. That patient was participating i
Show less
Read more
Impact Snapshot
Event Time:
DHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DHX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DHX alerts
High impacting DHI Group, Inc. news events
Weekly update
A roundup of the hottest topics
DHX
News
- DHI Group (DHX) had its "sell (d)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- DHI Group, Inc. to Report First Quarter Financial Results on May 5, 2026Business Wire
- Tokyo-based pharma giant shutters Seattle research facility, lays off 50 employees [Yahoo! Finance]Yahoo! Finance
- DHI Group (DHX) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
- Security Clearance Compensation Climbs to Record High Amid Federal Workforce Uncertainty, According to ClearanceJobs ReportBusiness Wire
DHX
Earnings
- 2/4/26 - Beat
DHX
Sec Filings
- 4/6/26 - Form 8-K
- 4/2/26 - Form DEF
- 3/2/26 - Form 8-K
- DHX's page on the SEC website